Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies... Show more
SYRS saw its Momentum Indicator move below the 0 level on March 21, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned negative. In of the 87 cases, the stock moved further down in the following days. The odds of a decline are at .
The Moving Average Convergence Divergence Histogram (MACD) for SYRS turned negative on March 24, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYRS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for SYRS entered a downward trend on March 05, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator entered the oversold zone -- be on the watch for SYRS's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
Following a +6 3-day Advance, the price is estimated to grow further. Considering data from situations where SYRS advanced for three days, in of 267 cases, the price rose further within the following month. The odds of a continued upward trend are .
SYRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
a therapeutics company focusing on discovering and developing novel gene control therapies
Industry Biotechnology